Table 3

CD8+ CTL clones recognizing unique minor histocompatibility antigens

PatientHLASample day *Therapy CTL clone Class I MHC restriction% specific lysis §RCC reactive
ABCPatientDonor
22, 258, 51w7, w14196None5C10(+) HLA-B51680+
2B3(+)HLA-A263-4+
420IFN-αClone 9HLA-A2862+
Clone 17HLA-A2633+
33, 247, 40w4, w761 CSP3A12HLA-B7501+
5E1ND481ND
2H4HLA-A3860
12D10(+)ND66-1ND
411, 2454, 67w1, w791CSP23G11(+)HLA-B54782ND
Pred24B4–4HLA-A11282
526, 327, 38w7, w12105CSP13A3HLA-B7780ND
Pred13H9(+)ND821ND
61, 28, 15w4, w735CSP1D8HLA-A2823+
12B3(+)HLA-A2694+
24B4–6ND644ND
58NoneNone
  • * Posttransplant day peripheral blood was collected as a source for in vitro T-cell culture.

  • Immune-modifying therapies administered at the time peripheral blood samples were obtained: CSP, cyclosporine; Pred, prednisone.

  • CTL clones were confirmed to be of donor origin by analysis with fluorescence in situ hybridization with Y chromosome-specific probes in sex-mismatched donor/recipient pairs or informative microsatellite markers in sex-matched donor-recipient pairs.

  • § Representative specific lysis of patient- and donor-derived EBV-LCL targets in a 4-hour chromium-release cytotoxicity assay with an E:T ratio of 10:1 or 5:1.

  • Isolation of additional clone(s) with the same specificity for allogeneic targets indicated by (+).

  • Posttransplant day relative to patient’s second transplant.

  • Abbreviation: ND, not determined.